Lee, Hyun Min http://orcid.org/0009-0007-4923-6275
Muhammad, Nefertiti
Lieu, Elizabeth L.
Cai, Feng
Mu, Jiawei
Ha, Yun-Sok
Cao, Guoshen http://orcid.org/0009-0007-7378-6306
Suchors, Chamey
Joves, Kenneth
Chronis, Constantinos
Li, Kailong http://orcid.org/0000-0001-5369-354X
Ducker, Gregory S. http://orcid.org/0000-0002-8651-6846
Olszewski, Kellen
Cai, Ling
Allison, Derek B.
Bachert, Sara E.
Ewing, William R.
Wong, Harvey http://orcid.org/0000-0003-1550-5071
Seo, Hyosun
Kim, Isaac Y.
Faubert, Brandon http://orcid.org/0000-0002-2886-886X
Kim, James
Kim, Jiyeon http://orcid.org/0000-0002-0138-1920
Funding for this research was provided by:
American Cancer Society (RSG-21-153-01-CCB)
American Lung Association (IA-828202)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1K22CA226676-01A1, P30CA177558, R00CA237724)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (1R37CA285640-01A1, 1R01CA258684)
U.S. Department of Health & Human Services | National Institutes of Health (P01HL160469, R00CA215307, 1R01CA196851, P50CA070907)
Article History
Received: 23 September 2022
Accepted: 16 May 2024
First Online: 14 June 2024
Change Date: 8 July 2024
Change Type: Update
Change Details: In the version of the article initially published, an earlier, incorrect version of Supplementary Table 9 was uploaded and has now been updated.
Competing interests
: W.R.E. and K.O. are employees of the Barer Institute, which is engaged in the clinical development of SHMT inhibitors. H.W. is a consultant for the following pharmaceutical companies: Genentech, Denali Therapeutics, Alector, Surrozen, Cleave Therapeutics, ORIC Pharmaceuticals, Barer Institute, Vincerx, Chinook and Cresenta. J.K. (UTSW) is on the scientific advisory board for Sanofi and is a consultant for Pulmatrix. The other authors declare no competing interests.